Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Evaluation of the Revised International Staging System (R-ISS) in an Independent Cohort of Unselected Patients with Multiple Myeloma

Efstathios Kastritis, MD, Evangelos Terpos, Maria Gavriatopoulou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Dimitrios Ziogas, Ioannis Panagiotidis, Despoina Fotiou, Dimitra Gika, Despoina Kalapanida, Eftychia Kafantari, Maria Roussou, Flora Zagouri, Stavroula Giannouli, Athanasios Zomas, Kostas Konstantopoulos, Meletios A. Dimopoulos

Blood (2015) 126 (23): 3045.

https://doi.org/10.1182/blood.V126.23.3045.3045

Published: 2015

Journal Articles

Validation of the Novel Criteria for the Definition of Symptomatic Myeloma: A Single Center Experience in 216 Patients with the Previous Diagnosis of Asymptomatic Disease

Efstathios Kastritis, MD, Evangelos Terpos, Maria Roussou, Vassilis Koutoulidis, Stavroula Giannouli, Maria Gavriatopoulou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Despoina Fotiou, Dimitrios Ziogas, Ioannis Panagiotidis, Despoina Kalapanida, Eirini Katodritou, Kostas Konstantopoulos, Lia A. Moulopoulos, Meletios A. Dimopoulos

Blood (2015) 126 (23): 4251.

https://doi.org/10.1182/blood.V126.23.4251.4251

Published: 2015

Journal Articles

Renal Outcomes in Patients with AL Amyloidosis: Evaluation of Prognostic Factors and Impact of Therapy with Novel Agents

Efstathios Kastritis, MD, Maria Roussou, Evangelos Terpos, Maria Gavriatopoulou, Evangelos Eleutherakis-Papaiakovou, Despoina Kalapanida, Sofoklis Kontogiannis, Theofanis Apostolou, Ioannis Boletis, Constantinos Pamboukas, Savvas Th. Toumanidis, Elektra Papadopoulou, Erasmia Psimenou, Meletios A. Dimopoulos, MD

Blood (2014) 124 (21): 2130.

https://doi.org/10.1182/blood.V124.21.2130.2130

Published: 2014

Journal Articles

Growth Differentiation Factor-15 in Patients with Light Chain (AL) Amyloidosis Has Independent Prognostic Significance and Adds Prognostic Information Related to Risk of Early Death and Renal Outcomes

Efstathios Kastritis, MD, Ioannis Papassotiriou, PhD, Evangelos Terpos, Athanassios Akalestos, Erasmia Psimenou, Filia Apostolakou, Maria Roussou, Maria Gavriatopoulou, Elisavet Kaldara, Evangelos Eleutherakis-Papaiakovou, Despoina Kalapanida, Constantinos Pamboucas, Evangelos Kostis, Sofoklis Kontogiannis, Savvas Th. Toumanidis, Ioannis Boletis, Meletios A. Dimopoulos

Blood (2014) 124 (21): 306.

https://doi.org/10.1182/blood.V124.21.306.306

Published: 2014

Journal Articles

Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy

Meletios A. Dimopoulos, Evangelos Terpos, Maria Gavriatopoulou, Despoina Kalapanida, Evangelos Eleutherakis-Papaiakovou, Maria Roussou, Despoina Mparmparoussi, Athanasios Zomas, Dimitra Gika, Zafiris Kartasis, Charis Matsouka, Evangelos Kostis, Sofoklis Kontogiannis, Kostas Konstantopoulos, Efstathios Kastritis, MD

Blood (2014) 124 (21): 4738.

https://doi.org/10.1182/blood.V124.21.4738.4738

Published: 2014

Journal Articles

The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma

Evangelos Terpos, Efstathios Kastritis, MD, Dimitrios Christoulas, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Despoina Kalapanida, Marios Bakogeorgos, Maria Roussou, Meletios A. Dimopoulos

Blood (2014) 124 (21): 3462.

https://doi.org/10.1182/blood.V124.21.3462.3462

Published: 2014

Journal Articles

Amplification of 1q21 Is Associated with Other High Risk Cytogenetic Abnormalities and Has No Independent Prognostic Significance in Patients Treated with Novel Agents

Efstathios Kastritis, MD, Evangelos Terpos, Maria Gavriatopoulou, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Marios Bakogeorgos, Despoina Kalapanida, Spyros Orfanopoulos, Vasiliki Bampali, Thaleia Meletiou, Dimitra Gika, Despoina Mparmparoussi, Charis Matsouka, Meletios A. Dimopoulos

Blood (2014) 124 (21): 3464.

https://doi.org/10.1182/blood.V124.21.3464.3464

Published: 2014

Journal Articles

Circulating Adamts-13 Is Reduced in Patients with Waldenstrom's Macroglobulinemia and Is Associated with Increased IgM Levels and Features of the Disease but Not with the Increased Levels of Von Willebrand Factor

Efstathios Kastritis, MD, Evangelos Terpos, Maria Gavriatopoulou, Chrysanthi Skevaki, Evangelos Eleutherakis-Papaiakovou, Despoina Kalapanida, Marios Bakogeorgos, Marianna Politou, Ioannis Papassotiriou, PhD, Meletios A. Dimopoulos

Blood (2014) 124 (21): 5741.

https://doi.org/10.1182/blood.V124.21.5741.5741

Published: 2014

Journal Articles

Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment

Meletios A. Dimopoulos, Maria Roussou, Evangelos Terpos, Erasmia Psimenou, Maria Gavriatopoulou, Evangelos Eleutherakis-Papaiakovou, Despoina Kalapanida, Marios Bakogeorgos, Despoina Mparmparoussi, Theodoros P. Vassilakopoulos, Dimitra Gika, Charis Matsouka, Ioannis Boletis, Kostas Konstantopoulos, Efstathios Kastritis, MD

Blood (2014) 124 (21): 4769.

https://doi.org/10.1182/blood.V124.21.4769.4769

Published: 2014

Journal Articles

The Cumulative Dose But Not The Frequency Of Infusions Is a Risk Factor For The Development Of Osteonecrosis Of The Jaw (ONJ) In Myeloma Patients Who Receive Zoledronic Acid (ZA)

Efstathios Kastritis, Evangelos Terpos, Ioannis Melakopoulos, Pelagia Melea, Despoina Kalapanida, Maria Roussou, Maria Gavriatopoulou, Nikolaos Kanellias, Marina Iakovaki, Dimitrios Christoulas, Dimitra Gika, Meletios A. Dimopoulos, MD

Blood (2013) 122 (21): 3196.

https://doi.org/10.1182/blood.V122.21.3196.3196

Published: 2013

Journal Articles

Validation Of Criteria For Renal Response In Patients With Multiple Myeloma (MM) Who Present With Severe Renal Dysfunction

Meletios A. Dimopoulos, MD, Evangelos Terpos, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Nikolaos Kanellias, Dimitrios Christoulas, Despoina Kalapanida, Despoina Mparmparoussi, Charis Matsouka, Sofoklis Kontogiannis, Evangelos Kostis, Erasmia Psimenou, Efstathios Kastritis

Blood (2013) 122 (21): 3176.

https://doi.org/10.1182/blood.V122.21.3176.3176

Published: 2013

Journal Articles

Very Early Death (<2 months) In Myeloma Is Associated With Advanced Age, Poor Performance Status and Reduced Use Of Novel Agents, While Early Death Within 12 Months Is Associated With High Risk Features Of Both The Disease and The Patient

Efstathios Kastritis, Evangelos Terpos, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Despoina Kalapanida, Magdalini Migkou, Nikolaos Kanellias, Dimitrios Christoulas, Dimitra Gika, Despoina Mparmparoussi, Charis Matsouka, Meletios A. Dimopoulos, MD

Blood (2013) 122 (21): 3195.

https://doi.org/10.1182/blood.V122.21.3195.3195

Published: 2013

NARROW

Evaluation of the Revised International Staging System (R-ISS) in an Independent Cohort of Unselected Patients with Multiple Myeloma

Validation of the Novel Criteria for the Definition of Symptomatic Myeloma: A Single Center Experience in 216 Patients with the Previous Diagnosis of Asymptomatic Disease

Renal Outcomes in Patients with AL Amyloidosis: Evaluation of Prognostic Factors and Impact of Therapy with Novel Agents

Growth Differentiation Factor-15 in Patients with Light Chain (AL) Amyloidosis Has Independent Prognostic Significance and Adds Prognostic Information Related to Risk of Early Death and Renal Outcomes

Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy

The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma

Amplification of 1q21 Is Associated with Other High Risk Cytogenetic Abnormalities and Has No Independent Prognostic Significance in Patients Treated with Novel Agents

Circulating Adamts-13 Is Reduced in Patients with Waldenstrom's Macroglobulinemia and Is Associated with Increased IgM Levels and Features of the Disease but Not with the Increased Levels of Von Willebrand Factor

Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment

The Cumulative Dose But Not The Frequency Of Infusions Is a Risk Factor For The Development Of Osteonecrosis Of The Jaw (ONJ) In Myeloma Patients Who Receive Zoledronic Acid (ZA)

Validation Of Criteria For Renal Response In Patients With Multiple Myeloma (MM) Who Present With Severe Renal Dysfunction

Very Early Death (<2 months) In Myeloma Is Associated With Advanced Age, Poor Performance Status and Reduced Use Of Novel Agents, While Early Death Within 12 Months Is Associated With High Risk Features Of Both The Disease and The Patient

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only